About Us | Introduction

Welcome to Trovagene

We are a molecular diagnostics company with unique intellectual property around the remarkable discovery that DNA & RNA, present in urine could be diagnostic of diseases such as cancer and infection. Trovagene’s revolutionary molecular diagnostic technology is setting out to change the way medicine is practiced, through simple, non-invasive diagnostic sampling of these nucleic acids leading to earlier detection of serious illness.

Key Points

‣Founded in 1999; based in San Diego, CA
‣Publicly traded molecular diagnostics company with a focus in oncology, prenatal diagnostics, infectious disease & transplant medicine
‣IP protects detection of trans-renal nucleic acids in urine (“DNA in urine”)
‣Develop urine-based molecular tests with a broad range of clinical utilities with potential to replace complex and less robust earlier technologies based on circulating cells and nucleic acids in blood

INTRODUCTION

Trovagene, Inc. is a publicly traded company molecular diagnostics company, with headquarters in San Diego, California. We are dedicated to the development and commercialization of unique, proprietary, molecular in-vitro diagnostics technologies.

The company’s founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine.

These cell-free nucleic fragments that pass through the kidney (“transrenal” or Tr-DNA/RNA) can be used as genetic markers of disease. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.

VALUE PROPOSITION

Targeting transrenal markers will allow us and our partners to develop genetic testing using non-invasive and easy-to-obtain urine samples rather than other more invasive methods, such as traditional blood testing. We are exploring a broad range of clinical utilities where transrenal DNA technology holds the potential to replace complex and less robust earlier technologies based on circulating cells and nucleic acids in blood

Trovagene is leveraging its platform to develop faster, cheaper, less invasive diagnostics, aligned with the current industry shift into personalized medicine. Our diagnostics will enhance the likelihood that the right patient gets the right treatment at the right time.

Transrenal molecular tests will make it easier to address important health problems worldwide and will lead to significant advancements in personalized medicine for improved patient care.

BUSINESS GOALS

Trovagene (from the Italian root word meaning “to find”) is initially targeting medical conditions in which the standard of care requires samples that are difficult, painful, invasive or dangerous to obtain and analyze as well as conditions for which no diagnostic tests currently exist. These targets include tests for the rapid and convenient screening for, detection and monitoring of infectious diseases, cancer, prenatal genetic testing, and the monitoring of organ/cell transplants.

INTELLECTUAL PROPERTY

Trovagene has a dominant patent position as it relates to transrenal molecular testing. We have issued U.S. and European patents that cover any and all testing for nucleic acid targets that pass through the kidney. In addition to these core patents we have numerous patent applications pending in the areas of cancer, infectious diseases, transplantation, prenatal and genetic testing. This patent position rivals the importance of the Roche PCR and Gen-Probe ribosomal RNA patents in the molecular diagnostic field.

Trovagene, INC. | TROV.PK